SAN DIEGO, Aug. 23 /PRNewswire/ -- eBioscience Corporation announced the appointment of Todd R. Nelson, Ph.D., to CEO of eBioscience, effective immediately. Dr. Nelson comes to eBioscience from Invitrogen Corporation where he was Vice President, Global Corporate Development.
Dr. Nelson will assume the role of CEO and Lily Lai, eBioscience's founder, will remain as President during a transition period. Nelson will also join eBioscience's Board of Directors.
Dr. Nelson commented: "I'm very excited about joining a fast growing company with the reputation and potential of eBioscience. The company's breakthrough products and enabling technologies are critical to the future of biotechnology and life science research."
Dr. Brian Seed, the Lead Director on eBioscience's Board of Directors, commented: "Todd has exceptional technical, financial and operating experience, and the energy and strategic vision to lead eBioscience through its next stage of growth."
Seed continued: "During Lily's tenure as President, eBioscience has grown from a start-up enterprise to a fast growing, profitable company that now has more than 1,000 products on the market, and a strong brand within the life science research community. We are grateful for her many contributions to eBioscience."
Todd R. Nelson was named Vice President Global Corporate Development and Strategy of Invitrogen Corporation in 2005. In addition to being responsible for mergers and acquisitions functions globally, Nelson held primary responsibility for the development and implementation of both corporate and divisional strategies for the organization on a world wide basis. Prior to that, he was Managing Director and Head, Global Life Sciences Corporate Strategy and Research at RBC Capital Markets, and First Vice President, Global Corporate Strategy and Economics at Merrill Lynch in New York.
Dr. Nelson has been a visible figure within the Life Sciences industry. During his more than 15 year tenure in the industry he has been responsible for the design and implementation of numerous corporate and operating strategies for various companies. In addition, he led the underwriting activities for more than 30 IPOs and has been involved in numerous value creating mergers and acquisitions, together totaling more than $7 billion. He has been a founder of several biotechnology companies and currently serves on the Board of Directors of Lokoya Capital Partners, LLC. Fluoropharma, Inc., and Blue Heron Biotechnologies, Inc.
Dr. Nelson has a Ph.D. from the University of Minnesota in molecular pathology and received advanced training as a senior fellow in clinical chemistry and molecular diagnostics at Mayo Clinic. Dr. Nelson received his MBA from the Carlson School of Business.
About eBioscience
eBioscience, headquartered in San Diego, California provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide. The company provides essential life science technologies for disease research and drug discovery. For more information, visit http://www.ebioscience.com.
eBioscience, Inc.CONTACT: Noosheen Alaverdi of eBioscience, Inc., +1-858-642-2046, ext.132, nalaverdi@ebioscience.com
Web site: http://www.ebioscience.com/
